Want to see HK:2561 full AI Analyst Report?
VISEN Pharmaceuticals (2561) Ratios
VISEN Pharmaceuticals Ratios
HK:2561's free cash flow for Q2 2026 was $-59.78M. For the 2026 fiscal year, HK:2561's free cash flow was decreased by $-177.00K and operating cash flow was $-59.60M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.47 | 4.26 | 7.22 | 8.15 | ― |
| Quick Ratio | 4.46 | 4.26 | 7.22 | 8.15 | ― |
| Cash Ratio | 3.00 | 3.90 | 6.71 | 7.17 | ― |
| Solvency Ratio | -1.13 | -3.38 | -4.58 | -3.18 | ― |
| Operating Cash Flow Ratio | -2.12 | -2.70 | -5.24 | -2.82 | ― |
| Short-Term Operating Cash Flow Coverage | -2.63 | 0.00 | 0.00 | 0.00 | ― |
| Net Current Asset Value | $ 727.12M | $ 170.03M | $ 321.20M | $ 622.92M | ― |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.01 | 0.01 | 0.01 | ― |
| Debt-to-Equity Ratio | 0.23 | 0.01 | 0.01 | 0.01 | ― |
| Debt-to-Capital Ratio | 0.19 | 0.01 | 0.01 | 0.01 | ― |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Financial Leverage Ratio | 1.28 | 1.22 | 1.14 | 1.14 | ― |
| Debt Service Coverage Ratio | -1.38 | -1103.20 | -764.22 | -453.88 | ― |
| Interest Coverage Ratio | -218.39 | -1081.85 | -437.95 | -578.81 | ― |
| Debt to Market Cap | 0.06 | 0.00 | 0.00 | 0.00 | ― |
| Interest Debt Per Share | 1.72 | 0.03 | 0.04 | 0.07 | ― |
| Net Debt to EBITDA | 1.93 | 1.13 | 1.42 | 2.21 | ― |
| Profitability Margins | |||||
| Gross Profit Margin | 11.51% | 100.00% | 100.00% | 100.00% | ― |
| EBIT Margin | -149208.29% | -6556.75% | 14934.27% | 12547.78% | ― |
| EBITDA Margin | -147239.14% | -6395.93% | 14515.10% | 12225.89% | ― |
| Operating Profit Margin | -145329.04% | -6272.16% | 8318.15% | 15591.21% | ― |
| Pretax Profit Margin | -153589.68% | -6562.55% | 14953.27% | 12574.72% | ― |
| Net Profit Margin | -153589.68% | -6562.55% | 14953.27% | 12574.72% | ― |
| Continuous Operations Profit Margin | -153589.68% | -6562.55% | 14953.27% | 12574.72% | ― |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | ― |
| EBT Per EBIT | 105.68% | 104.63% | 179.77% | 80.65% | ― |
| Return on Assets (ROA) | -25.25% | -62.02% | -56.24% | -38.98% | ― |
| Return on Equity (ROE) | -32.38% | -75.53% | -63.85% | -44.28% | ― |
| Return on Capital Employed (ROCE) | -30.47% | -72.08% | -35.42% | -54.79% | ― |
| Return on Invested Capital (ROIC) | -24.87% | -71.49% | -35.19% | -54.40% | ― |
| Return on Tangible Assets | -25.28% | -63.90% | -57.46% | -39.55% | ― |
| Earnings Yield | -8.08% | -3.01% | -4.28% | -5.08% | ― |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Payables Turnover | 0.03 | 0.00 | 0.00 | 0.00 | ― |
| Inventory Turnover | 0.09 | 0.00 | 0.00 | 0.00 | ― |
| Fixed Asset Turnover | 0.02 | 1.07 | -0.38 | -0.29 | ― |
| Asset Turnover | 0.00 | 0.01 | -0.00 | -0.00 | ― |
| Working Capital Turnover Ratio | 0.00 | 0.01 | -0.00 | 0.00 | ― |
| Cash Conversion Cycle | 555495.24 | 0.00 | 0.00 | 0.00 | ― |
| Days of Sales Outstanding | 564917.56 | 0.00 | 0.00 | 0.00 | ― |
| Days of Inventory Outstanding | 3923.20 | 0.00 | 0.00 | 0.00 | ― |
| Days of Payables Outstanding | 13345.52 | 0.00 | 0.00 | 0.00 | ― |
| Operating Cycle | 568840.76 | 0.00 | 0.00 | 0.00 | ― |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.32 | -1.50 | -2.90 | -2.63 | ― |
| Free Cash Flow Per Share | -4.34 | -1.51 | -2.90 | -2.65 | ― |
| Dividend Paid and CapEx Coverage Ratio | -173.95 | -1203.91 | -521.75 | -139.61 | ― |
| Capital Expenditure Coverage Ratio | -173.95 | -1203.91 | -521.75 | -139.61 | ― |
| Operating Cash Flow Coverage Ratio | -2.53 | -59.76 | -74.35 | -41.12 | ― |
| Operating Cash Flow to Sales Ratio | -2784.71 | -50.72 | 162.56 | 107.29 | ― |
| Free Cash Flow Yield | -14.74% | -2.33% | -4.66% | -4.37% | ― |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.38 | -33.20 | -23.39 | -19.69 | ― |
| Price-to-Sales (P/S) Ratio | 19001.90 | 2178.79 | -3497.46 | -2475.39 | ― |
| Price-to-Book (P/B) Ratio | 4.01 | 25.08 | 14.93 | 8.72 | ― |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.78 | -42.92 | -21.47 | -22.91 | ― |
| Price-to-Operating Cash Flow Ratio | -6.82 | -42.95 | -21.52 | -23.07 | ― |
| Price-to-Earnings Growth (PEG) Ratio | -0.56 | 1.23 | 1.72 | 0.00 | ― |
| Enterprise Value Multiple | -10.98 | -32.93 | -22.67 | -18.04 | ― |
| Enterprise Value | 2.60B | 5.85B | 5.49B | 5.07B | ― |
| EV to EBITDA | -10.98 | -32.93 | -22.67 | -18.04 | ― |
| EV to Sales | 16165.74 | 2106.33 | -3291.27 | -2205.39 | ― |
| EV to Free Cash Flow | -5.77 | -41.49 | -20.21 | -20.41 | ― |
| EV to Operating Cash Flow | -5.81 | -41.53 | -20.25 | -20.56 | ― |
| Tangible Book Value Per Share | 7.34 | 2.48 | 4.07 | 6.86 | ― |
| Shareholders’ Equity Per Share | 7.35 | 2.58 | 4.17 | 6.97 | ― |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Revenue Per Share | 0.00 | 0.03 | -0.02 | -0.02 | ― |
| Net Income Per Share | -2.38 | -1.95 | -2.67 | -3.09 | ― |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | ― |
| Interest Burden | 1.03 | 1.00 | 1.00 | 1.00 | ― |
| Research & Development to Revenue | 566.57 | 32.60 | -34.57 | -78.13 | ― |
| SG&A to Revenue | 910.40 | 31.12 | -9.80 | -18.07 | ― |
| Stock-Based Compensation to Revenue | 475.10 | 11.80 | 7.35 | -40.69 | ― |
| Income Quality | 1.77 | 0.77 | 1.09 | 0.85 | ― |
Currency in CNY